Modality
Gene Editing
MOA
PRMT5i
Target
PARP
Pathway
Proteasome
WM
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
Aug 2018
→ Dec 2027
Phase 2Current
NCT06385082
2,650 pts·WM
2018-08→2027-12·Recruiting
NCT03321170
587 pts·WM
2020-12→TBD·Not yet recruiting
3,237 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-041.7y awayPh2 Data· WM
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Recruit…
P2
Not yet…
Catalysts
Ph2 Data
2027-12-04 · 1.7y away
WM
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06385082 | Phase 2 | WM | Recruiting | 2650 | HAM-D |
| NCT03321170 | Phase 2 | WM | Not yet recr... | 587 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C |